MedTrace Logo

Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura

NCT01104428 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2010-09-08

No results posted yet for this study

Summary

Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns on Traditional Chinese Medicine(TCM) clinical research scheme evaluation of HSP, evaluates the renal damage and disease recurrence as the end event, and comes to the evaluation through the comparative study that the vantage point of the scheme of syndrome differentiation and treatment in detoxification, cooling blood and removing blood stasis to the conventional treatments can reduce kidney damage and recurrence rate.

Conditions

  • Purpura, Schoenlein-Henoch

Interventions

DRUG

Placebo

granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods

DRUG

"ziying" granules

granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods

Sponsors & Collaborators

  • Dongzhimen Hospital, Beijing

    collaborator OTHER

  • Shenyang Hospital of Integrated Traditional and westen Medicine

    collaborator UNKNOWN

  • Dalian Children's Hospital

    collaborator OTHER

  • Liaoning University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • zhang jun, master · Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  • zhao lijun, master · Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  • wang shaojie, master · Dalian Children's Hospital

  • ma liming, master · Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  • li tienan, master · Shenyang Hospital of Integrated Traditional and westen Medicine

  • xu rongqian, master · Dongzhimen Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01104428 on ClinicalTrials.gov